Table A19:

Fluoropyrimidine Treatment Effectiveness Study Results—Treatment Response and Survival

Author, Year N (Carriers/Wild-Type)	Treatment Response, n (%)	Disease Progression, n (%)	Overall Survival, n (%)	Progression-Free Survival, n (%)
Henricks et al, 201911 74 (37/37) DPYD∗2A	Disease controlled Carriers: 12 (60) Wild-type: 10 (48) Complete response Carriers: 0 Wild-type: 1 (5) Partial response Carriers: 4 (20) Wild-type: 6 (29) Stable disease Carriers: 8 (40) Wild-type: 3 (14) P > .99 (overall for treatment response and progressive disease)	Carriers: 8 (40) Wild-type: 11 (30) P > .99 (overall for treatment response and progressive disease)	Median (range), months Carriers: 27 (1—83) Wild-type: 24 (0.7—97) HR: 0.82 (95% CI 0.47—1.43) P = .47	Median (range), months Carriers: 14 (0.7—83) Wild-type: 10 (0.2—97) HR: 0.83 (95% CI 0.47—1.50) P = .54

Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not applicable; NR, not reported.